Clinical Trial Update: A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) [Phase 3]

View source ↗

Summary

Phase 3 study of brentuximab vedotin in high-risk residual Hodgkin lymphoma after stem cell transplant completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Disease, Hodgkin | Phase 3 | Status: COMPLETED | Results posted: 2015-11-11